In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the world's largest association of facial plastic and reconstructive surgeons, has released its highly anticipated 2024 ...

The New Science of Ageing and the Quest for Immortality', he talked about ethics & realities of anti-ageing research and how to live a healthy, long life.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Purdue researchers were awarded the Presidential Early Career Award for Scientists and Engineers by the U.S. government ...

The key is the ligand — that’s the general word for whatever chemical messenger or ... For GLP-1 receptors, it’s GLP-1. Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the ...

The key is the ligand — that’s the general word for whatever chemical ... it’s GLP-1. Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1, binding ...

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” A Type 2 diabetes medication that can also aid in weight loss ...

AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. Molecular glue ...